Trial Profile
A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Advanced Haematological Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Karyopharm Therapeutics; NPM Pharma
- 21 Mar 2020 Results of non-compartmental analyses conducted using pre-dose and post-dose plasma samples to characterize the PK of selinexor and KPT-375 (10-fold less active metabolite) were presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 04 Dec 2017 Results assessing the safety and efficacy of selinexor in patients with relapsed or refractory multiple myeloma and Waldenstrom's macroglobulinemia (n=81) published in the Blood
- 31 Mar 2017 Status changed from active, no longer recruiting to completed.